Literature DB >> 14499963

Antisense knockdown of spinal-mGluR1 reduces the sustained phase of formalin-induced nociceptive responses.

Kazuko Noda1, Takeshi Anzai, Masanori Ogata, Hisanao Akita, Taichi Ogura, Makoto Saji.   

Abstract

To examine the role of mGluR1 (a subunit of the group I metabotropic glutamate receptor) in the nociceptive responses of rats following a subcutaneous injection of formalin into the plantar surface of the hind paw, we delivered antisense oligonucleotides (ODNs) against mGluR1 into the rat lumbar spinal cord (L3-L5) intrathecally using an HVJ-liposome-mediated gene transfer method. Rats treated with a single injection of mGluR1 antisense ODNs into the intrathecal space of the lumbar spinal cord showed a marked reduction of the early-sustained phase of formalin-induced nociceptive responses, but not of their acute phase. The reduction of nociceptive behavioral responses became apparent at day 2 after the antisense treatment and lasted for 2 days. This corresponded to a long-lasting down-regulation (46%) of mGluR1 expression in the lumbar cord. This down-regulated mGluR1 was observed at day 2 and persisted until day 4 after the intrathecal infusion of mGluR1 antisense ODN. In contrast, rats treated with mGluR1 sense or mismatch ODNs showed none of these changes. These results suggest that mGluR1 may play a crucial role in the sustained nociception of formalin-induced behavioral responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499963     DOI: 10.1016/s0006-8993(03)03330-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn.

Authors:  Xue Jun Liu; Michael W Salter
Journal:  Eur J Neurosci       Date:  2010-07-11       Impact factor: 3.386

2.  Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.

Authors:  O El-Kouhen; S G Lehto; J B Pan; R Chang; S J Baker; C Zhong; P R Hollingsworth; J P Mikusa; E A Cronin; K L Chu; S P McGaraughty; M E Uchic; L N Miller; N M Rodell; M Patel; P Bhatia; M Mezler; T Kolasa; G Z Zheng; G B Fox; A O Stewart; M W Decker; R B Moreland; J D Brioni; P Honore
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

3.  The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles.

Authors:  Geoffrey B Varty; Mariagrazia Grilli; Angelo Forlani; Silva Fredduzzi; Michael E Grzelak; Donald H Guthrie; Robert A Hodgson; Sherry X Lu; Elisa Nicolussi; Annamarie J Pond; Eric M Parker; John C Hunter; Guy A Higgins; Angelo Reggiani; Rosalia Bertorelli
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

4.  Spinal Metabotropic Glutamate Receptors (mGluRs) are Involved in the Melittin-induced Nociception in Rats.

Authors:  Chul Hyun Cho; Hong Kee Shin
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

Review 5.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

6.  Therapeutic potential of metabotropic glutamate receptor modulators.

Authors:  N Hovelsø; F Sotty; L P Montezinho; P S Pinheiro; K F Herrik; A Mørk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.